
Cloud or on-premises ICSR/safety database for collecting, processing and reporting human and veterinary adverse events to global regulators, targeted at mid-sized pharma, CROs, generics manufacturers and animal-health companies, differentiated by configurable workflows usable without IT staff and dual human/veterinary coverage on one platform.
Ennov's pharmacovigilance product line comprises modules — "Ennov Doc for PV," "Case Intake & Management," "Reporting & Data Analysis," "Signal Detection & Management" — on top of the safety database marketed as "Ennov PV-Works" (with separate "PV-Works Human" and "PV-Works Vet" editions). The Vet edition supports EUVeterinary XML and FDA CVM HL7 formats.
Ennov entered the PV market by acquiring UK-based Assured Information Systems in July 2014. PV-Works subsequently became the Ennov pharmacovigilance solution. Document archives under pv247.com / pv247.ennov.com retain the AIS letterhead.
Functionally the suite covers ICSR intake (manual entry, E2B import, PDF/web case-capture forms with auto-translation), MedDRA-coded case processing, workflow routing, electronic submission to EMA and FDA via AS2 gateway, aggregate reports (PSUR, DSUR, PBRER, PADER, CIOMS, MedWatch 3500), and an integrated signal-detection module (PV-Analyzer / Signal Detection & Management) calculating PRR, ROR and MGPS disproportionality measures.
Two pharma-specific editions: PV-Works Human (human drug ICSRs) and PV-Works Vet (veterinary ICSRs supporting EUVeterinary XML and FDA CVM HL7 formats).
Deployment: single-tenant private cloud (Microsoft Azure or OVHcloud) or on-premises. Vendor states customers can switch between deployment options. No claim of multi-tenant SaaS architecture. "Data can be hosted locally for total flexibility". Specific Azure/OVH region list not published.
Access: 100% web-based, modern browser; mobile-optimised intake forms for smartphone/tablet; lightweight PDF intake form alternative. Native mobile applications not advertised. SSO: login realm uses Keycloak (login.ennov.com/realms/EnnovSupport), which supports SAML 2.0 and OIDC. Specific support for AzureAD/Okta for customer tenants is not explicitly published.
APIs: REST API exists — signal-detection module "populated via our REST API." GraphQL, webhook catalogue, rate limits and SDKs are undisclosed. Data standards: ICH E2B(R2) and E2B(R3); EVCTM; FDA VAERS variant character set; FDA1932 (vet); FDA CVM HL7; MedDRA; VeDDRA.
Scale claims: Ennov-wide 450+ life-sciences customers, 500,000 users (corporate, not PV-only). PV-specific user / ICSR-volume metrics not published.
No public list price is published. Subscription pricing applies for cloud; a perpetual licence is implied as available for on-premises, given the vendor's statement that "you can switch between deployment options at any time." Per-user or per-tenant pricing breakdown is undisclosed. Demo available on request. No productised free trial is advertised. Reported deal sizes, minimum commitments, setup fees, and validation-support fees are not publicly disclosed.
Timeline by org size not benchmarked publicly. Ennov asserts a "production-ready system in a relatively short period of time" using a "well-defined, repeatable delivery framework" and claims "98.5% of projects delivered on time and within budget."
Implementation, training and support are sold as separate professional services. Role-based hands-on training, virtual delivery, e-learning, and "Train-the-Trainer" model. Customer support sold as ongoing service with 24/7 ticket submission and business-hour live support keyed to UK and US helpdesks.
Migration: E2B import supports ingest of historical case data sent in E2B XML by another vendor — files "may be imported directly into PV-Works." Named legacy-system migration tooling is not published. A 2025 case study describes an animal-health customer of "almost 20 years" who migrated PV operations from an on-prem installation to Ennov SaaS.
PharmaSpotter assessment from published vendor and third-party sources. No user reviews are on file for this product.
Users report that the configurable workflow lets non-IT staff change processes without coding — "create new or change existing business workflows without any IT technical skills." Users report responsive customer support and a tightly linked product family ("ENNOV solutions (DOC, DOSSIER, PROCESS, RIM..) are linked and connected, allowing incredible possibilities"). In PV-specific testimonials, users report a "supportive" and "respectful" partnership style (Pure Drug Safety).
Users report that as a 100% web-based product, Ennov is occasionally affected by latency and connection issues. One CTMS reviewer reported Ennov Clinical (separate product) was the worst eCRF they had used — a signal of potential UX variation by module. PV-specific reviews are too few to draw strong conclusions; published PV-Works reviews are sparse. No published GAMP 5 categorisation; no SOC 2 Type II report; no pre-validated multi-tenant SaaS claim.
Share your experience with Ennov Pharmacovigilance Suite (PV-Works) anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackPublicly disclosed pharmaceutical and biotech organizations
Jump to section